<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15306963</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Francés Muñoz, E</dc:author>
<dc:author>Monte Boque, E</dc:author>
<dc:author>Muñoz Gómez, M C</dc:author>
<dc:author>Martínez-Costa Pérez, R</dc:author>
<dc:author>Ramos-López, J F</dc:author>
<dc:author>Cisneros Lanuza, A L</dc:author>
<dc:author>Menezo Rozalén, J L</dc:author>
<dc:author>López-Sánchez, E V</dc:author>
<dc:description xml:lang="en">PURPOSE To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN). METHODS Three patients with CIN were treated with topical MMC 0.02%. Our follow-up period was twelve months (range 8-18 months). RESULTS CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture. CONCLUSIONS Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2004 Aug </dc:date>
<dc:title xml:lang="es">Tratamiento de las neoplasias conjuntivales intraepiteliales con colirio de mitomicina C al 0,02%</dc:title>
<dc:title xml:lang="en">[Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
